ALLK
Allakos Inc
Halal Rating :
Last Price
$0.90
Last updated:
Market Cap
-
7D Change
4.05%
1 Year Change
-25.62%
Company Overview
Industries
Exchange
Next Earnings Date
Allakos Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company's lead monoclonal antibody product candidate is lirentelimab (AK002), which is being evaluated for the treatment of various indications including eosinophilic gastritis, eosinophilic duodenitis, and atopic dermatitis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Allakos Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.